Acupuncture for peripheral neuropathy induced by paclitaxel in early-stage breast cancer: a randomized, parallel, controlled, blinded study in a Brazilian Oncologic Center (PACLILIN Study)
Supportive Care in Cancer · 2026-02 · 34 (2)
DOI: 10.1007/s00520-026-10315-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 16.01.2026. Verfasst von Lin I Ter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Brasileiro de Controle Do Câncer, São Paulo, Brazil. lin.ter@npeibcc.org.br. Hauptthemen laut MEDLINE: Breast Neoplasms, Paclitaxel, Peripheral Nervous System Diseases, Acupuncture Therapy. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event without effective treatment, just recommended dose reduction, interruption, or modification of the chemotherapy regimen. We conducted a randomized controlled study to evaluate the therapeutic effects of acupuncture. METHODS: Sixty patients with stage I, II, and III breast cancer who developed CIPN due to neoadjuvant or adjuvant paclitaxel were randomized 1:1 to receive true vs sham acupuncture once per week for 8 weeks. The primary outcome was the response to Neuropathic Pain Symptom Inventory (NPSI), and the secondary outcomes were Visual Analog Scale (VAS) and Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-taxane) quality of life scale. The questionnaires were administered during weeks 1, 4, 6, and 8 (in person) and week 12 (by telephone). RESULTS: For the primary outcome, there were statistically significant differences at week 8 favoring the true acupuncture group for the subscales pressure pain (mean 0.11 vs 0.33; p = 0.01), paroxysmal pain (mean 0.13 vs 0.30; p = 0.037), paresthesia/dysesthesia (mean 0.21 vs 0.43; p = 0.007) and the total score (mean 0.14 vs 0.33; p = 0.02). Regarding secondary outcomes on the VAS scale, there was statistically significant difference favoring the true acupuncture group at visit 8 (mean 3.0 vs 6.0; p = 0.001), but without differences in FACT-taxane, either total score or subscales. There were no differences in any of the outcomes at week 12. CONCLUSION: CIPN-related symptoms in patients with breast cancer who received paclitaxel were reduced by true acupuncture compared with sham acupuncture in the eighth week (ClinicalTrials.gov ID NCT04461977).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Brasileiro de Controle Do Câncer, São Paulo, Brazil. lin.ter@npeibcc.org.br.
- Instituto Brasileiro de Controle Do Câncer, São Paulo, Brazil.
- Centro de Investigação Translacional Em Oncologia, Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil.
- Departamento de Patologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Zitieren
APA
Ter, L. I., Yamada, A. M. T. D., do Nascimento Martins Basilio, A., López, R. V. M., & Hsing, W. T. (2026). Acupuncture for peripheral neuropathy induced by paclitaxel in early-stage breast cancer: a randomized, parallel, controlled, blinded study in a Brazilian Oncologic Center (PACLILIN Study). Supportive Care in Cancer, 34(2). https://doi.org/10.1007/s00520-026-10315-8
Vancouver
Ter LI, Yamada AMTD, do Nascimento Martins Basilio A, López RVM, Hsing WT. Acupuncture for peripheral neuropathy induced by paclitaxel in early-stage breast cancer: a randomized, parallel, controlled, blinded study in a Brazilian Oncologic Center (PACLILIN Study). Supportive Care in Cancer. 2026;34(2). doi:10.1007/s00520-026-10315-8
BibTeX
@article{Ter2026,
author = {Ter, Lin I and Yamada, Alayne Magalhães Trindade Domingues and do Nascimento Martins Basilio, Adriana and López, Rossana Verónica Mendoza and Hsing, Wu Tu},
title = {Acupuncture for peripheral neuropathy induced by paclitaxel in early-stage breast cancer: a randomized, parallel, controlled, blinded study in a Brazilian Oncologic Center (PACLILIN Study)},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s00520-026-10315-8}
}
EUVIMED